Source link : https://www.newshealth.biz/health-news/subcutaneous-c5-inhibitor-approved-for-pnh/
The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and children 13 years and up with a body weight of at least 40 kg (~88 lb), the anti-C5 monoclonal antibody was engineered to be recycled in the bloodstream […]
Author : News Health
Publish date : 2024-06-24 17:39:14
Copyright for syndicated content belongs to the linked Source.
Categories